Genetic susceptibility to adverse drug reactions

被引:209
作者
Pirmohamed, M [1 ]
Park, BK [1 ]
机构
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England
关键词
D O I
10.1016/S0165-6147(00)01717-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Adverse drug reactions (ADRs) are a major clinical problem. Genetic factors can determine individual susceptibility to both dose-dependent and dose-independent ADRs. Determinants of susceptibility include kinetic factors, such as gene polymorphisms in cytochrome P450 enzymes, and dynamic factors, such as polymorphisms in drug targets. The relative importance of these factors will depend on the nature of the ADR; however, it is likely that more then one gene will be involved in most instances. In the future, whole genome single nucleotide polymorphism (SNP) profiling might allow an unbiased method of determining genetic predisposing factors for ADRs, but might be limited by the lack of adequate numbers of patient samples. The overall clinical utility of genotyping in preventing ADRs needs to be proven by the use of prospective randomized controlled clinical trials.
引用
收藏
页码:298 / 305
页数:8
相关论文
共 88 条
  • [61] Idiosyncratic drug reactions - Metabolic bioactivation as a pathogenic mechanism
    Pirmohamed, M
    Madden, S
    Park, BK
    [J]. CLINICAL PHARMACOKINETICS, 1996, 31 (03) : 215 - 230
  • [62] PIRMOHAMED M, 1997, PRINCIPLES MED BIOL, P737
  • [63] PIRMOHAMED M, IN PRESS NEUROLOGY
  • [64] Multicentre randomised study of computerised anticoagulant dosage
    Poller, L
    Shiach, CR
    MacCallum, PK
    Johansen, AM
    Münster, AM
    Magalhaes, A
    Jespersen, J
    [J]. LANCET, 1998, 352 (9139) : 1505 - 1509
  • [65] PRICEEVANS DA, 1989, PHARMACOL THERAPEUT, V42, P157
  • [66] Rawlins M, 1991, TXB ADVERSE DRUG REA, P18
  • [67] Relling MV, 1999, BLOOD, V93, P2817
  • [68] Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
    Relling, MV
    Hancock, ML
    Rivera, GK
    Sandlund, JT
    Ribeiro, RC
    Krynetski, EY
    Pui, CH
    Evans, WE
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (23): : 2001 - 2008
  • [69] High incidence of secondary brain tumours after radiotherapy and antimetabolites
    Relling, MV
    Rubnitz, JE
    Rivera, GK
    Boyett, JM
    Hancock, ML
    Felix, CA
    Kun, LE
    Walter, AW
    Evans, WE
    Pui, CH
    [J]. LANCET, 1999, 354 (9172) : 34 - 39
  • [70] HYDROXYLATION OF WARFARIN BY HUMAN CDNA-EXPRESSED CYTOCHROME-P-450 - A ROLE FOR P-4502C9 IN THE ETIOLOGY OF (S)-WARFARIN DRUG-INTERACTIONS
    RETTIE, AE
    KORZEKWA, KR
    KUNZE, KL
    LAWRENCE, RF
    EDDY, AC
    AOYAMA, T
    GELBOIN, HV
    GONZALEZ, FJ
    TRAGER, WF
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 1992, 5 (01) : 54 - 59